Astria Therapeutics (NASDAQ:ATXS) Earns “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Astria Therapeutics (NASDAQ:ATXS) in a research report report published on Thursday,Benzinga reports. HC Wainwright currently has a $16.00 price objective on the biotechnology company’s stock.

A number of other equities research analysts have also recently issued reports on the stock. Oppenheimer increased their target price on shares of Astria Therapeutics from $26.00 to $28.00 and gave the stock an “outperform” rating in a research report on Thursday, November 14th. JMP Securities began coverage on shares of Astria Therapeutics in a research report on Friday, January 31st. They set an “outperform” rating and a $26.00 target price for the company. Finally, Citizens Jmp upgraded shares of Astria Therapeutics to a “strong-buy” rating in a research report on Friday, January 31st. Six research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Astria Therapeutics currently has a consensus rating of “Buy” and an average target price of $25.67.

Astria Therapeutics Stock Down 0.6 %

Shares of Astria Therapeutics stock opened at $6.31 on Thursday. The stock has a market capitalization of $356.07 million, a P/E ratio of -3.02 and a beta of 0.68. The company has a 50-day simple moving average of $7.76 and a 200 day simple moving average of $9.91. Astria Therapeutics has a 12-month low of $6.24 and a 12-month high of $16.90.

Institutional Investors Weigh In On Astria Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ATXS. Fcpm Iii Services B.V. acquired a new stake in Astria Therapeutics in the 4th quarter valued at about $25,680,000. FMR LLC boosted its stake in shares of Astria Therapeutics by 29.2% in the 3rd quarter. FMR LLC now owns 7,822,275 shares of the biotechnology company’s stock valued at $86,123,000 after purchasing an additional 1,767,714 shares during the last quarter. Vestal Point Capital LP boosted its stake in shares of Astria Therapeutics by 23.1% in the 3rd quarter. Vestal Point Capital LP now owns 4,000,000 shares of the biotechnology company’s stock valued at $44,040,000 after purchasing an additional 750,000 shares during the last quarter. Redmile Group LLC bought a new position in shares of Astria Therapeutics in the 3rd quarter valued at about $3,423,000. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of Astria Therapeutics by 152.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 314,265 shares of the biotechnology company’s stock valued at $3,460,000 after purchasing an additional 189,727 shares during the last quarter. Institutional investors and hedge funds own 98.98% of the company’s stock.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.